Founded in 2009, Leeds-based Arterius is developing a next-generation bioresorbable cardiovascular scaffold (stent) with an emerging market-leading clinical profile. The founding directors have significant experience in the development of medical devices and in the cardiovascular devices field in particular. The development team is supported by a consortium of experts comprising, amongst others, clinical advisory team; computational design group at Southampton University; polymer process engineering at Bradford University and pre-clinical and clinical institutions. Arterius has recently completed the pre-clinical trials and, on the back of these, believes that this collaboration has delivered a next generation drug eluting fully biodegradable stent with a market leading profile.
Arterius was established by Dr Kadem Al-Lamee and Alistair Taylor to exploit opportunities in the $8.1bn coronary stent market. The company has worked in partnership with a consortium of academic contributors consisting of the Computational Design Group at Southampton University, UK; the Industrial Research Centre in Polymer Engineering, Bradford University, UK; and the Department of Surface Characterisation and Drug Distribution at Nottingham University, UK to design, manufacture and put into pre-clinical evaluation a family of novel vascular scaffold stents, under the trademarked name ArterioSorb™.